COVID-19 has become a global health threat, and the need for a safe and effective vaccine is critical.
Trial ID: 2019nCov-301
Novavax Commitment to Diversity & Inclusion
This clinical trial is testing whether the investigational NVX-CoV2373 vaccine candidate will prevent COVID-19
With over 100 study sites, we are looking for up to 30,000 participants from various backgrounds to take part in this clinical trial. We have partnered with study sites who are dedicated to reaching individuals who by virtue of their life circumstances (i.e., living or working conditions) are considered at substantial risk of exposure to and infection with COVID-19. Within this high-risk population of individuals, prioritization will be given to the enrollment of important groups that have been disproportionately impacted by COVID-19. These groups include members of the Black/African American, LatinX or Native American communities, people living with medical conditions commonly associated with complications arising from COVID-19 disease (e.g., obesity, chronic kidney or lung disease, cardiovascular disease and Type 2 diabetes), and the elderly.![]()
This COVID-19 clinical trial is testing whether the investigational NVX-CoV2373 vaccine candidate will prevent COVID-19. It will compare this vaccine with a placebo, a substance that contains no active medication.
Participants who qualify for the study will receive:
Given that certain populations can respond differently to medical therapies, it is extremely important that this clinical trial include people from all races and ethnicities to ensure the vaccine is safe and effective for everyone to use.
We’ll check to see if you are eligible by asking you some questions.
Participation for this clinical trial is divded into 3 periods:
You will be randomly assigned (by chance) to receive either the study vaccine or placebo. A placebo does not contain any active ingredient. Neither you nor the study doctor will know which group you are in or which injection you receive. Each participant will receive 2 injections, 21 days apart.
You will need to travel to one of up to 114 sites in the U.S. taking part in this clinical trial. U.S. sites are located in:
Actively Recruiting
Currently Inactive
We’ll check to see if you are eligible by asking you some questions.